Alectos Therapeutics is a private pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of serious human diseases. The company’s focus centres on preclinical target validation, hit-to-lead optimization, and IND-enabling studies. Alectos develops new, innovative strategies to address medical conditions for which there are no effective treatments.
Alectos began operations as a spin-off from research conducted at Simon Fraser University. The company’s most advanced program is directed toward developing modulators of OGA, a novel target that is believed to be involved in the development of Alzheimer’s disease, Progressive Supranuclear Palsy (PSP), and potentially other disorders. This program is partnered with Merck, and is the subject of an ongoing collaboration between Merck and Alectos focused on clinical development.
As part of its pipeline, Alectos is also actively advancing discovery-stage programs in oncology and neurology, including development of pharmacological chaperones of glucocerebrosidase (GCase) for Parkinson’s disease.